论文部分内容阅读
rn目的探讨盐酸氨溴索支气管肺泡灌洗联合肺表面活性物质(PS)治疗新生儿胎粪吸入综合征(MAS)的疗效及安全性。方法 65例MAS患儿随机分为治疗组(A组,32例)和对照组(B组,33例),分别在治疗0、24、72h检测两组患儿支气管肺泡灌洗液(BALF)中肺表面活性蛋白(SP)A、SP-D及血管内皮生长因子(VEGF)的含量,并同时记录呼吸机参数、血气分析结果和呼吸机使用时间等临床指标。结果治疗24、48h后,A组患儿BALF中SP-A、SP-D含量逐渐升高,高于B组(P“,”Objective To investigate the curative effect and security of bronchoalveolar lavage with ambroxol hydrochloride plus pulmonary surfactant(PS) on meconium aspiration syndrome(MAS) in newborns.Methods A total of 65 infants with MAS was randomly divided into two groups of A(bronchoalveolar lavage with ambroxol hydrochloride plus PS,32 cases) and B(normal controls,33 cases).The concentrations of surfactant protein A(SP-A),SP-D and vascular endothelial growth factor(VEGF) in the bronchoalveolar lavage fluid(BALF) were detected before and at 24 h and 72 h after treatment.ResultsAt 24 h and 72 h after treatment,the concentrations of SP-A and SP-D in the BALF were grandually increased in group A,which were higher than those in group B(P<0.05),while the content of VEGF in group A was lower than that in group B(P<0.05).Moreover,compared with group B,the incidence of pulmonary barotauma leakage,mortality,hospital stay,duration of mechanical ventilation and oxygen supplement were all significantly decreased(P<0.05).ConclusionBronchoalveolar lavage with ambroxol hydrochloride plus PS in the treatment of MAS can reduce the lung injury,improve the oxygenation,shorten the duration of mechanical ventilation and oxygen supplement and decrease the mortality probably via enhancing the endogenous PS,increasing the content of SP-A and SP-D and inhibiting the release of VEGF.